Decision Resources, Inc.

Launch of Alzhemed, Flurizan will drive dementia drug market, reports indicates

Published in Health Business Week, November 18th, 2005

Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that the launch of Neurochem's Alzhemed (NC-758) and Myriad Genetics' Flurizan (R-flurbiprofen) will be the primary drivers in growing the dementia drug treatment market by 11% annually over the next 10 years.

The new Pharmacor report, "Strategic Overview of the Dementia Drug Market 2004-2014," forecasts that by 2014 Alzhemed and Flurizan, the first disease-modifying treatments for dementia, will account for 57% of drug sales in this market.

The report also finds that sales of acetylcholinesterase inhibitors including Eisai/Pfizer's Aricept,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2005-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry